HEALTH & TREATMENT
OPZELURA®: A Guide to the First FDA-Approved Treatment for Repigmentation of Nonsegmental Vitiligo
How you choose to live in your skin is up to you. If that includes treatment, you know these decisions can bring up questions and a lot to consider. That’s why we partnered with Incyte to bring you a guide to OPZELURA® (ruxolitinib) cream 1.5%. Not because you need to treat—but so you can be informed.
OPZELURA has warnings for risks including serious infections, increased risk of death, cancer and immune system problems, major cardiovascular events (eg, heart attack or stroke), and blood clots. See full Important Safety Information, and the Full Prescribing Information, including Boxed Warning, and Medication Guide for Opzelura on Opzelura.com and within the guide.
Sponsored by Incyte. OPZELURA, the OPZELURA logo and Incyte are registered trademarks of Incyte. © 2026, Incyte. OPZ-1978 09/26